



HIV/AIDS Medication Treatment

Quick Reference Guide

2026

Table of Contents

LANDSCAPE OF HIV/AIDS MEDICATIONS IN VBC	3
Prevalence and Clinical Context - ART in Older Adults with HIV	4
Cost Estimate Snapshot - HIV ART Regimens.....	5
Direct Savings and Value Impact Matrix	7
INDICATIONS AND CONTRAINDICATIONS	8
Indications.....	8
Contraindications.....	11
Essential PCP Pretreatment Checks Before ART Initiation	15
DOSE RECOMMENDATIONS	16
Dose Escalation and Treatment Intensification Criteria	16
Duration of ART	18
HIV ART UTILIZATION FRAMEWORK IN VALUE-BASED CARE	22
A Closed Loop DAA VBC Pathway for PCPs	22
Actionable Cost Optimization Strategy	24
Regimen De-Escalation and Optimization	25
Non-Pharmacological Intervention Strategies	27
Patient-Centered Conversation Framework	29
HCC and Quality Alignment.....	30
Key HEDIS/MIPs/PQA Measures.....	30
TEN KEY TAKEAWAYS FOR HIV DAA THERAPIES	31
AAVBC SUMMARY AND CONCLUSION.....	33
REFERENCES	34

LANDSCAPE OF HIV/AIDS MEDICATIONS IN VBC

Antiretroviral therapy (ART) is a lifelong, oral (and increasingly injectable) medication regimen used to treat HIV infection.^{1,2} Its primary and most well-established benefit is **achieving and maintaining sustained virologic suppression**, defined as a plasma **HIV RNA** (viral load) **below 200 copies/mL**, which improves overall health and effectively eliminates sexual transmission of HIV.^{1,3} Virologic suppression with ART is associated with **dramatically reduced rates of AIDS-defining events**, a narrowing of the life expectancy gap to within 5 years of the general population for those who achieve CD4 counts above 500 cells/ μ L, and **significant reductions in non-AIDS complications** including cardiovascular disease, non-AIDS malignancies, renal disease, and neurocognitive decline.^{1,2,4} In the landmark **START trial**, the highest absolute risk reduction of serious AIDS and non-AIDS events with immediate ART was observed in participants aged 50 years and older.⁵

HIV infection remains a significant public health challenge in the United States, with an estimated **1.2 million adults** currently living with HIV.⁶ Approximately **30,000–35,000** new infections occur annually, with **persistent racial and ethnic disparities**—Black/African American and Hispanic/Latino populations are disproportionately affected.⁷ Critically for primary care providers, the demographics of the **HIV-positive population are shifting**: in 2022, **38%** of people with HIV were **aged 55 years or older**, and **13.2%** were **aged 65 or older**, proportions that are expected to increase steadily.⁸ Older adults accounted for **1 in 6** new HIV diagnoses in 2022, and **more than half** of older adults newly diagnosed with HIV present at a **late stage of disease** (CD4 count <350 cells/ μ L)—a lost opportunity for **early treatment and prevention of transmission**.^{9,10}

HIV-associated morbidity in older adults is substantial. People with HIV have a **1.5- to 2-fold** increased risk of **atherosclerotic cardiovascular disease (ASCVD)**, with incident ASCVD occurring approximately a decade earlier than in the general population.⁸ **Heart disease and cancer** are the leading causes of death in older people with HIV.⁸ **Additional comorbidities**—including chronic kidney disease, osteoporosis, diabetes, neurocognitive impairment, depression, and frailty—occur at **higher rates and earlier ages** compared to age-matched HIV-negative individuals.^{11,12} A simulation study projects that by 2030, **45%** of people with HIV on ART will be living with **two or more** physical comorbidities and **64%** with **at least one** mental health comorbidity.¹³ The economic burden is correspondingly high: the estimated average discounted lifetime HIV-related medical cost per person is approximately **\$420,000**, with ART medications comprising roughly **74%** of total costs.^{14,15} Annual wholesale acquisition costs (WAC) for first-line ART regimens recommended for most people with HIV range from approximately **\$23,000 to \$39,000**, having nearly **doubled over the preceding decade**; even with newer generic options, all guideline-recommended initial regimens **exceed \$36,000 per year** at list price. Medicare spending on people with HIV was estimated at **\$11 billion** in fiscal year 2019, approximately half on Part D prescription drugs. **Antiretrovirals are one of six protected drug classes under Medicare Part D**, requiring plans to provide access to all or substantially all FDA-approved antiretrovirals. Beginning in 2025, the Inflation Reduction Act established a **\$2,000 annual out-of-pocket spending cap** for Part D, and several antiretroviral drugs are potentially subject to **Medicare price negotiation** beginning in 2028.



AAVBC PERSPECTIVE

AAVBC Tip: High-value HIV care in older adults begins with **timely diagnosis and rapid ART initiation**. The **USPSTF** recommends HIV screening for all individuals aged 15–65 years and older adults at increased risk (**A recommendation**).¹⁶ However, **other US guidelines are more inclusive**: the **CDC** recommends routine opt-out screening **through age 64**,¹⁰ the **DHHS/OARAC** guidelines emphasize routine screening of **asymptomatic older adults** given

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

Subscribe Now

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time